Advertisement
Canada markets open in 7 hours 15 minutes

  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     

  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • CAD/USD

    0.7281
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    79.40
    +0.41 (+0.52%)
     

  • Bitcoin CAD

    84,748.20
    -1,140.16 (-1.33%)
     

  • CMC Crypto 200

    1,313.62
    +13.52 (+1.04%)
     

  • GOLD FUTURES

    2,321.90
    -0.40 (-0.02%)
     

  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     

  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     

  • NASDAQ futures

    18,144.25
    -42.25 (-0.23%)
     

  • VOLATILITY

    13.00
    -0.23 (-1.74%)
     

  • FTSE

    8,354.05
    +40.38 (+0.49%)
     

  • NIKKEI 225

    38,114.70
    -87.67 (-0.23%)
     

  • CAD/EUR

    0.6776
    0.0000 (0.00%)
     

PlayStation boosts Sony's sales; Amazon tumbles on earnings miss; Gilead lower on drug-price war

Seana Smith
·Host

Time for your daily dose of trending tickers, the stocks you're following based on your Yahoo Finance ticker searches.

Sony

Shares of Sony (SNE) are getting a big boost today. A surge in PlayStation 4 sales helped compensate for a drop in mobile sales as Sony reported a 33.5% gain in quarterly profit. Sony Pictures also turned in an impressive quarter, with movies like “Hotel Transylvania 2” and “Spectre” performing well at the box office.

Amazon

Despite delivering its largest quarterly profit in its 20-year history, Amazon (AMZN) investors are not happy. The stock is taking a hit after the online retail giant fell short of Wall Street expectations. Amazon’s 22% revenue jump just missed estimates, marking the sixth straight year it has come up short for this period.

ADVERTISEMENT

Gilead

A new price war that could be heating up in the pharmaceutical space is weighing on Gilead’s (GILD) stock. Shares of the pharmaceutical giant are trading lower after the FDA approved Merck’s new drug for treating hepatitis C. Merck’s treatment is more than 30% cheaper than Gilead’s two hepatitis C drugs. Long-time CEO John Martin has also announced he will be stepping down as chief executive.